Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 January 2026, 15:44 HKT/SGT
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Highest ranked global pharmaceutical company

TOKYO, Jan 21, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s tenth inclusion on the list. Ranked 36th, Eisai is the highest ranking among global pharmaceutical companies as well as the highest ranking Japanese company listed in the Global 100 (please visit here for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 8,200 of the world’s major corporations based on the United Nation’s Sustainable Development Goals (SDGs). Since 2005, companies ranking among the top 100 in the world have been announced each year. The Global 100 companies are evaluated for sustainable revenue and its growth, and sustainable investment as defined by Corporate Knights based on publicly disclosed data from financial filings, integrated reports, or other such channels. Eisai was highly evaluated, particularly in indicators such as sustainable revenue and investment achieved through business activities, and its system reflecting sustainability targets in executive compensation.

Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its sustainability initiatives and increasing non-financial value.

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 17, 2026 23:24 HKT/SGT
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 15, 2026 23:18 HKT/SGT
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15, 2026 22:51 HKT/SGT
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15, 2026 22:21 HKT/SGT
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13, 2026 23:06 HKT/SGT
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 2, 2026 21:45 HKT/SGT
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 2, 2026 21:01 HKT/SGT
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
June 17, 2026 12:28 HKT/SGT
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
May 21, 2026 23:23 HKT/SGT
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 19:52 HKT/SGT
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: